Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis (ULTRA)
調査の概要
詳細な説明
This is an open-lable, single arm study of the ultrasonographic monitoring of response to infliximab in patients with rheumatoid arthritis. Approximately 120 subjects will be enrolled. Subjects will receive infliximab 3mg/kg intravenous infusion at 0, 2, 6 week, and then repeated every 8 weeks until 24 weeks.
The efficacy assessment is observed by ACR response, HAQ, DAS28, sharp scores and US assessment at 0,2,6,14, 22, and 24weeks and ultrosonographic and radiographic assessments are conducted at 0, 6,and 24weeks.
Subjects will be followed for AEs and SAEs up to 8 weeks following the last study treatment administration (see Section 6).
The end of study is defined as the time the last subject completes the 24 weeks visit.
研究の種類
入学 (予想される)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
Beijing
-
Beijing、Beijing、中国、100000
- 募集
- Perking Union Medical College Hospital
-
コンタクト:
- Xiaomei Leng, MD
- 電話番号:+86-13681057089
- メール:lengxm@gmail.com
-
主任研究者:
- Xiaomei Leng, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- age 18-65 years, male or female and who are capable of providing informed consent, which must be obtained prior to any study-related procedures.
- Those who have a definitive diagnosis of RA based on the criteria of American College of Rheumatology in 1987 and have moderate to severe disease (DAS28 more than 3.2).
- Patients using oral corticosteroids, must have been on a stable dose of prednisone 10mg/day or its equivalent for at least 4 weeks prior to screening. If currently not using corticosteroids the patient must have not received corticosteroids for at least 4 weeks prior to screening.
- Patients using DMARDs, must have been on a stable dose for at least 12 weeks prior to screening. If currently not using DMARDs the patient must have not received DMARDs for at least 12 weeks prior to screening.
- If using NSAIDs or other analgesics for RA, must be on a stable dose for at least 2 weeks prior to the first administration of study agent.
Exclusion Criteria:
- Patient who has a known hypersensitivity to human immunoglobulin proteins or other components of infliximab.
- Patient who suffers from systemic inflammatory disease whose signs and symptoms are expected to affect the evaluation of the study drug.
- Patient who has a history of receiving infliximab or any other biologics.
- Patient who has stage IV RA.
- Patient who has had or is on live viral or bacterial vaccinations within 4 weeks to study entry.
- Patient who ever suffered from chronic or recurrent infection, including but not limited to: chronic kidney infection, chronic thoracic cavity infection (eg. bronchiectasis), nasosinusitis, recurrent urinary tract infection, open, drain or dermal infected wound.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
The primary objective of this study is to evaluate the efficacy of treatment with infliximab on synovitis in RA patients using ultrasonography at 24 weeks.
時間枠:24 weeks
|
24 weeks
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
estimate and visualize the efficacy of treatment with infliximab in RA patients using ultrasonography
時間枠:6, 24 weeks
|
6, 24 weeks
|
investigate the validity and sensitivity of ultrasonography assessment of joints inflammation in patients with RA compared with sharp scores
|
|
3) observe the relationship between ultrasonography assessment and DAS28, ACR20 and sharp scores and other clinical index
|
協力者と研究者
協力者
捜査官
- 主任研究者:Yan Zhao, MD、Perking Union Medical College Hospital
- 主任研究者:Xiaomei Leng, MD、Perking Union Medical College Hospital
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
infliximabの臨床試験
-
Onze Lieve Vrouwe GasthuisSanteonわからない